Study #2024-1478
RASolute 302: A phase 3 multicenter, open-label, randomized study of RMC-6236 versus investigator's choice of standard of care therapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC)
MD Anderson Study Status
Enrolling
Treatment Agent
RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin
Description
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Study phase:
Phase III
Physician name:
Shubham Pant
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-404-4637
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.